The Synthetic Routes of Saracatinib

Saracatinib is a selective inhibitor of the tyrosine kinase receptor found in the Tec family, particularly c-Met.
It is used in cancer treatment and has shown potential in the treatment of various types of cancer such as hepatocellular carcinoma, lung cancer, and gastric cancer.
The synthesis of Saracatinib has been a subject of extensive research in the chemical industry due to its potential therapeutic applications.
In this article, we will discuss the synthetic routes of Saracatinib.

One of the most common methods for synthesizing Saracatinib is through a five-step synthesis route, which involves the synthesis of the intermediate, S-26372, followed by a series of reactions that lead to the formation of Saracatinib.
The first step involves the synthesis of N-Boc-L-proline, which is then converted into N-Boc-L-amino acid through a series of reactions.
This intermediate is then treated with hydrogen chloride to generate the desired carboxylic acid, which is then coupled with a variety of amines to form the S-26372 intermediate.
The final step involves the removal of the Boc protecting group and the formation of Saracatinib through a series of chemical reactions.

Another synthesis route for Saracatinib involves a four-step process that involves the synthesis of the intermediate, S-23779.
This intermediate is then treated with a variety of reagents to form Saracatinib.
The first step in this process involves the synthesis of N-Boc-L-amino acid, which is then treated with 1,1,1,3,3,3-hexamethylguanidine to form the S-23779 intermediate.
The final step involves the removal of the Boc protecting group and the formation of Saracatinib.

In addition to the above synthesis routes, there are also other methods for synthesizing Saracatinib that have been reported in the scientific literature.
One such method involves the synthesis of Saracatinib through a four-step process that involves the synthesis of the intermediate, S-28555.
This intermediate is then treated with hydrogen chloride to generate the carboxylic acid, which is then coupled with a variety of amines to form the S-28555 intermediate.
The final step involves the removal of the Boc protecting group and the formation of Saracatinib.

Another synthesis route for Saracatinib involves the use of a modified Suzuki reaction to synthesize the compound.
In this method, a boronic acid derivative is used as the coupling partner, which allows for the efficient and selective formation of Saracatinib.

In conclusion, Saracatinib is a potential cancer therapeutic that can be synthesized through a variety of methods.
The five-step synthesis route is one of the most common methods for synthesizing Saracatinib, but there are also other methods that have been reported in the scientific literature.
These synthesis routes provide a starting point for the large-scale synthesis of Saracatinib and may lead to further optimization to improve efficiency and selectivity.
The development of new synthesis routes for Saracatinib and other potential cancer therapeutics is an active area of research in the chemical industry and has the potential to lead to new treatments for cancer in the future.